Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC
Audio podcast with highlights from a live webinar covering available clinical data and approved treatments for ROS1-altered TKI-naive advanced non-small-cell lung cancer (NSCLC). Listen to the experts review and discuss their perspectives and summarize clinical data in support of guideline-recommended first-line treatment approaches.
Decera Clinical Education Oncology Podcast · Jessica J. Lin MD, Alice T. Shaw MD PhD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available clinical data in support of frontline treatments for ROS1-altered NSCLC including:
- Efficacy and safety data for crizotinib, entrectinib, and repotrectinib in patients with ROS1-altered advanced NSCLC
- Long-term safety observations for crizotinib and entrectinib
- CNS activity of entrectinib and repotrectinib in patients with brain metastases
- Repotrectinib activity in ROS1-TKI resistance mutations
Program faculty:
Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Alice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
Resources:
To download the slides associated with this podcast discussion, please visit the program page.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.